Janus Henderson Group PLC Acquires Shares of 17,200 Bioventus Inc. (NYSE:BVS)

Janus Henderson Group PLC bought a new position in Bioventus Inc. (NYSE:BVS) in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund bought 17,200 shares of the company’s stock, valued at approximately $181,000.

Several other hedge funds and other institutional investors have also recently made changes to their positions in BVS. Tower Research Capital LLC TRC raised its holdings in Bioventus by 106.1% in the 4th quarter. Tower Research Capital LLC TRC now owns 3,469 shares of the company’s stock worth $36,000 after acquiring an additional 1,786 shares during the last quarter. Plato Investment Management Ltd bought a new stake in shares of Bioventus in the 4th quarter worth $38,000. KLP Kapitalforvaltning AS purchased a new position in shares of Bioventus in the fourth quarter worth $75,000. Quantbot Technologies LP bought a new position in shares of Bioventus during the fourth quarter valued at $103,000. Finally, Arizona State Retirement System purchased a new stake in shares of Bioventus during the fourth quarter valued at $109,000. Institutional investors own 62.94% of the company’s stock.

Bioventus Price Performance

NYSE BVS opened at $6.53 on Monday. The business’s fifty day moving average price is $7.79 and its 200-day moving average price is $9.62. The stock has a market capitalization of $536.40 million, a price-to-earnings ratio of -10.70 and a beta of 0.95. The company has a debt-to-equity ratio of 1.85, a current ratio of 1.41 and a quick ratio of 0.99. Bioventus Inc. has a 1-year low of $5.28 and a 1-year high of $14.38.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on BVS shares. Craig Hallum set a $15.00 target price on Bioventus and gave the stock a “buy” rating in a research report on Wednesday, May 7th. Canaccord Genuity Group reissued a “buy” rating and set a $15.00 price objective on shares of Bioventus in a report on Monday, March 17th.

Insider Buying and Selling

In other news, CFO Mark Leonard Singleton sold 3,875 shares of the stock in a transaction that occurred on Friday, April 11th. The shares were sold at an average price of $7.57, for a total value of $29,333.75. Following the transaction, the chief financial officer now owns 141,088 shares in the company, valued at $1,068,036.16. This represents a 2.67% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders sold 13,330 shares of company stock valued at $115,291 over the last 90 days. Company insiders own 32.90% of the company’s stock.

Bioventus Company Profile

Bioventus Inc, a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain.